Supplementation of l-Alanyl-l-Glutamine and Fish Oil Improves Body Composition and Quality of Life in Patients With Chronic Heart Failure

Circulation: Heart Failure

Volumn 8, Issue 6, 2015, Pages 1077-1087

  Wu, Christina ^a   Kato, Tomoko S ^b   Ji, Ruiping ^a   Zizola, Cynthia ^a   Brunjes, Danielle L ^a   Deng, Yue ^a   Akashi, Hirokazu ^c   Armstrong, Hilary F ^a   Kennel, Peter J ^a   Thomas, Tiffany ^a   Forman, Daniel E ^a   Hall, Jennifer ^a   Chokshi, Aalap ^a   Bartels, Matthew N ^a   Mancini, Donna ^a   Seres, David ^a   Schulze, P Christian ^a  

^a Department of Medicine   (United States)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c NONE

Author keywords

echocardiography; heart failure; metabolism; muscle, skeletal; quality of life

Indexed keywords

AMINO ACID DERIVATIVE; CARNITINE PALMITOYLTRANSFERASE I; CERAMIDE; DIPEPTIDE; FATTY ACID; FISH OIL; GLUCOSE TRANSPORTER 4; LEVO ALANYL LEVO GLUTAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLACEBO; PYRUVATE DEHYDROGENASE KINASE 4; SAFFLOWER OIL; UNCLASSIFIED DRUG; GLUTAMINE;

6 MINUTE WALK TEST; ADULT; AMINO ACID ANALYSIS; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOCARDIOGRAPH; FATTY ACID OXIDATION; FEMALE; FOLLOW UP; FUNCTION TEST; FUNCTIONAL MUSCLE TESTING; GENE EXPRESSION; GRIP STRENGTH; HEART FAILURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEAN BODY WEIGHT; LIPID ANALYSIS; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MILK; MORPHOMETRICS; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE METABOLISM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; CHRONIC DISEASE; EXERCISE TOLERANCE; HAND STRENGTH; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; TREATMENT OUTCOME;

BODY COMPOSITION; CHRONIC DISEASE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; FISH OILS; GLUTAMINE; HAND STRENGTH; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84947804753     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.115.002073     Document Type: Article

References (41)

1. Francis GS, Greenberg BH, Hsu DT, Jaski BE, Jessup M, Le Winter MM, Pagani FD, Pina IL, Semigran MJ, Walsh MN, Wiener DH, Yancy CW, Jr. Accf/aha/acp/hfsa/ishlt 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: A report of the accf/aha/acp task force on clinical competence and training. Circulation. 2010;122:644-672.
2. L evine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241. doi: 10.1056/NEJM199007263230405.
3. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S, Kato T, Khan R, Takayama H, Knöll R, Milting H, Chung CS, Jorde U, Naka Y, Mancini DM, Goldberg IJ, Schulze PC. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation. 2012;125:2844-2853. doi: 10.1161/CIRCULATIONAHA.111.060889.
4. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46:1019-1026. doi: 10.1016/j.jacc.2005.02.093.
5. Drexler H, Riede U, Münzel T, König H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85:1751-1759.
6. Hambrecht R, Schulze PC, Gielen S, Linke A, Möbius-Winkler S, Yu J, Kratzsch J Jü, Baldauf G, Busse MW, Schubert A, Adams V, Schuler G. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2002;39:1175-1181.
7. Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, Lopaschuk GD. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ Heart Fail. 2013;6:1039-1048. doi: 10.1161/CIRCHEARTFAILURE.112.000228.
8. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050-1053. doi: 10.1016/S0140-6736(96)07015-8.
9. GISSI-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-1230. doi: 10.1016/S0140-6736(08)61239-8.
10. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57:870-879. doi: 10.1016/j. jacc.2010.11.017.
11. Smith GI, Atherton P, Reeds DN, Mohammed BS, Rankin D, Rennie MJ, Mittendorfer B. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011;93:402-412. doi: 10.3945/ajcn.110.005611.
12. Shahzad K, Chokshi A, Schulze PC. Supplementation of glutamine and omega-3 polyunsaturated fatty acids as a novel therapeutic intervention targeting metabolic dysfunction and exercise intolerance in patients with heart failure. Curr Clin Pharmacol. 2011;6:288-294.
13. Engel JM, Mühling J, Kwapisz M, Heidt M. Glutamine administration in patients undergoing cardiac surgery and the influence on blood glutathione levels. Acta Anaesthesiol Scand. 2009;53:1317-1323. doi: 10.1111/j.1399-6576.2009.02084.x.
14. Carubelli V, Castrini AI, Lazzarini V, Gheorghiade M, Metra M, Lombardi C. Amino acids and derivatives, a new treatment of chronic heart failure? Heart Fail Rev. 2015;20:39-51. doi: 10.1007/s10741-014-9436-9.
15. Lombardi C, Carubelli V, Lazzarini V, Vizzardi E, Quinzani F, Guidetti F, Rovetta R, Nodari S, Gheorghiade M, Metra M. Effects of oral amino Acid supplements on functional capacity in patients with chronic heart failure. Clin Med Insights Cardiol. 2014;8:39-44. doi: 10.4137/CMC.S14016.
16. van Norren K, Kegler D, Argilés JM, Luiking Y, Gorselink M, Laviano A, Arts K, Faber J, Jansen H, van der Beek EM, van Helvoort A. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumourbearing cachectic mice. Br J Cancer. 2009;100:713-722. doi: 10.1038/sj.bjc.6604905.
17. L indenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN; Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1-194. doi: 10.1016/j.cardfail.2010.04.004.
18. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245-1255.
19. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124:1017-1025.
20. Clugston RD, Jiang H, Lee MX, Piantedosi R, Yuen JJ, Ramakrishnan R, Lewis MJ, Gottesman ME, Huang LS, Goldberg IJ, Berk PD, Blaner WS. Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. J Lipid Res. 2011;52:2021-2031. doi: 10.1194/jlr.M017368.
21. Choi CS, Befroy DE, Codella R, Kim S, Reznick RM, Hwang YJ, Liu ZX, Lee HY, Distefano A, Samuel VT, Zhang D, Cline GW, Handschin C, Lin J, Petersen KF, Spiegelman BM, Shulman GI. Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc Natl Acad Sci U S A. 2008;105:19926-19931. doi: 10.1073/pnas.0810339105.
22. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJ, Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998;4:1269-1275. doi: 10.1038/3253.
23. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, Goldberg IJ. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008;49:2101-2112. doi: 10.1194/jlr.M800147-JLR200.
24. Drosatos K, Bharadwaj KG, Lymperopoulos A, Ikeda S, Khan R, Hu Y, Agarwal R, Yu S, Jiang H, Steinberg SF, Blaner WS, Koch WJ, Goldberg IJ. Cardiomyocyte lipids impair β-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab. 2011;300:E489-E499. doi: 10.1152/ajpendo.00569.2010.
25. Li G, Hernandez-Ono A, Crooke RM, Graham MJ, Ginsberg HN. Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res. 2011;52:971-981. doi: 10.1194/jlr.M013748.
26. Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res. 2012;53:2525-2545. doi: 10.1194/jlr.R027904.
27. Chen J, Shearer GC, Chen Q, Healy CL, Beyer AJ, Nareddy VB, Gerdes AM, Harris WS, O'Connell TD, Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation. 2011;123:584-593. doi: 10.1161/CIRCULATIONAHA.110.971853.
28. Khan RS, Chokshi A, Drosatos K, Jiang H, Yu S, Harris CR, Schulze PC, Homma S, Blaner WS, Shulman GI, Huang LS, Goldberg IJ. Fish oil selectively improves heart function in a mouse model of lipid-induced cardiomyopathy. J Cardiovasc Pharmacol. 2013;61:345-354. doi: 10.1097/FJC.0b013e318283d845.
29. Stumvoll M, Perriello G, Meyer C, Gerich J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int. 1999;55:778-792. doi: 10.1046/j.1523-1755.1999.055003778.x.
30. Bowtell JL, Bruce M. Glutamine: an anaplerotic precursor. Nutrition. 2002;18:222-224.
31. Gibala MJ. Regulation of skeletal muscle amino acid metabolism during exercise. Int J Sport Nutr Exerc Metab. 2001;11:87-108.
32. Khogali SE, Pringle SD, Weryk BV, Rennie MJ. Is glutamine beneficial in ischemic heart disease? Nutrition. 2002;18:123-126.
33. Scognamiglio R, Avogaro A, Negut C, Piccolotto R, de Kreutzenberg SV, Tiengo A. The effects of oral amino acid intake on ambulatory capacity in elderly subjects. Aging Clin Exp Res. 2004;16:443-447.
34. Aquilani R, Viglio S, Iadarola P, Opasich C, Testa A, Dioguardi FS, Pasini E. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol. 2008;101(11A):104E- 110E. doi: 10.1016/j.amjcard.2008.03.008.
35. Aquilani R, Opasich C, Gualco A, Verri M, Testa A, Pasini E, Viglio S, Iadarola P, Pastoris O, Dossena M, Boschi F. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail. 2008;10:1127-1135. doi: 10.1016/j.ejheart.2008.09.002.
36. Scognamiglio R, Negut C, Piccolotto R, Dioguardi FS, Tiengo A, Avogaro A. Effects of oral amino acid supplementation on myocardial function in patients with type 2 diabetes mellitus. Am Heart J. 2004;147:1106-1112. doi: 10.1016/j.ahj.2003.12.003.
37. Rogero MM, Tirapegui J, Pedrosa RG, Castro IA, Pires IS. Effect of alanyl-glutamine supplementation on plasma and tissue glutamine concentrations in rats submitted to exhaustive exercise. Nutrition. 2006;22:564-571. doi: 10.1016/j.nut.2005.11.002.
38. Grau T, Bonet A, Miñambres E, Piñeiro L, Irles JA, Robles A, Acosta J, Herrero I, Palacios V, Lopez J, Blesa A, Martínez P; Metabolism, Nutrition Working Group, SEMICYUC, Spain. The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients. Crit Care Med. 2011;39:1263-1268. doi: 10.1097/CCM.0b013e31820eb774.
39. Alves WF, Aguiar EE, Guimarães SB, da Silva Filho AR, Pinheiro PM, Soares Gdos S, de Vasconcelos PR. L-alanyl-glutamine preoperative infusion in patients with critical limb ischemia subjected to distal revascularization reduces tissue damage and protects from oxidative stress. Ann Vasc Surg. 2010;24:461-467. doi: 10.1016/j.avsg.2010.01.005.
40. Stangl R, Szijártó A, Ónody P, Tamás J, Tátrai M, Hegedus V, Blázovics A, Lotz G, Kiss A, Módis K, Gero D, Szabó C, Kupcsulik P, Harsányi L. Reduction of liver ischemia-reperfusion injury via glutamine pretreatment. J Surg Res. 2011;166:95-103. doi: 10.1016/j.jss.2009.09.047.
41. Hoffman JR, Ratamess NA, Kang J, Rashti SL, Kelly N, Gonzalez AM, Stec M, Anderson S, Bailey BL, Yamamoto LM, Hom LL, Kupchak BR, Faigenbaum AD, Maresh CM. Examination of the efficacy of acute L-alanyl-L-glutamine ingestion during hydration stress in endurance exercise. J Int Soc Sports Nutr. 2010;7:8. doi: 10.1186/1550-2783-7-8.